Jongphil Kim

18PUBLICATIONS
95CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 21, 2026
Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|Sep 22, 2025
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.

Mark B Meads, Xiaohong Zhao, David Noyes

|Dec 09, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes.

Ciara L Freeman, Jerald Noble, Meghan Menges

|Oct 25, 2024
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.

Joseph Pidala, Jongphil Kim, Denise Kalos

|Jul 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.

Joseph Pidala, Shernan G Holtan, Kelly Walton

Pageof 3

Frequent Collaborators

8 joint publications

Taiga Nishihori

7 joint publications

Nelli Bejanyan

6 joint publications

Hany Elmariah

5 joint publications

Aleksandr Lazaryan